Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08ROQ
|
||||
| Former ID |
DNC001258
|
||||
| Drug Name |
S-25585
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Eating disorders reduction in food intake [ICD9: 307.5; ICD10:F50] | Investigative | [1] | ||
| Company |
Servier
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H29F3N4O6S
|
||||
| Canonical SMILES |
C1CC(CCC1CNS(=O)(=O)C2CCC(CC2[N+](=O)[O-])C(F)(F)F)C(=O<br />)NNC(=O)C3=CC=CC=C3
|
||||
| InChI |
1S/C22H29F3N4O6S/c23-22(24,25)17-10-11-19(18(12-17)29(32)33)36(34,35)26-13-14-6-8-16(9-7-14)21(31)28-27-20(30)15-4-2-1-3-5-15/h1-5,14,16-19,26H,6-13H2,(H,27,30)(H,28,31)
|
||||
| InChIKey |
MODMVZPKMVZXFO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Neuropeptide Y receptor 5 | Target Info | Antagonist | [1] | |
| Neuropeptide Y receptor type 1 | Target Info | Antagonist | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interactionhsa04024:cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| NetPath Pathway | FSH Signaling Pathway | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| Endothelin Pathways | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.